Hydrix Secures $3.7M in Contracts Led by SynCardia Artificial Heart Deal
Hydrix secures $3.7 million in contracts as SynCardia artificial heart deal anchors 2026 growth
Hydrix Limited (ASX: HYD) has signed $3.7 million in contracts during the opening quarter of calendar year 2026, with the bulk of new business coming from international clients in cardiac and advanced surgical robotics sectors. The Hydrix SynCardia artificial heart contract, valued at $2.5 million, forms the centrepiece of this pipeline and will support development of the company’s first generation fully implantable total artificial heart. All contracted revenue is expected to be recognised during CY2026, following 12 to 18 months of international business development efforts.
The quarter-to-date contract signings represent new client wins rather than renewals, indicating Hydrix’s engineering capability is gaining traction in high-value offshore medical device segments. The company’s multi-discipline engineering team has been targeting what it describes as safety-critical, lifesaving medical devices.
Revenue from these contracts will flow through during calendar year 2026, providing near-term visibility after a first half where revenues came in below the prior corresponding period due to project timing.
When big ASX news breaks, our subscribers know first
What is a total artificial heart and why does the SynCardia contract matter?
A total artificial heart (TAH) is a mechanical device that replaces both lower chambers of a failing heart. Unlike ventricular assist devices that support a weakened heart, a TAH completely takes over the heart’s pumping function, typically serving as a bridge to transplant for patients with end-stage heart failure.
SynCardia develops total artificial hearts, and the “fully implantable” distinction is significant. Current generation TAHs often require external components such as pneumatic drivers that patients must carry, limiting mobility and quality of life. A fully implantable device would have all components housed within the body, representing a substantial advancement in cardiac technology.
Hydrix’s role involves providing the engineering expertise to develop this next-generation device. The $2.5 million first-stage development contract positions the company at the frontier of cardiac technology development, with potential for follow-on contracts if the program progresses through subsequent development phases.
Total artificial hearts address a growing clinical need. With organ donor shortages limiting transplant availability, devices that can provide longer-term support while maintaining patient mobility represent an expanding market opportunity.
Revenue pipeline builds with $40 million potential over three years
Hydrix reported H1 FY26 revenue of $4.9 million, down from $5.7 million in the prior corresponding period. The company attributed this decline to the timing of new client project commencement and completion of existing development programmes, rather than loss of business.
The forward-looking picture appears more robust. Hydrix currently has 15 active client engagements with the potential to deliver approximately $40 million in revenues over the next 2 to 3 years. The $3.7 million already contracted in early CY2026 provides early evidence of pipeline conversion, representing roughly 9% of the total potential opportunity.
| Metric | H1 FY26 | Prior Corresponding Period |
|---|---|---|
| Revenue | $4.9m | $5.7m |
| Cash on hand | $0.6m | $0.3m |
| CY2026 contracts signed (to date) | $3.7m | — |
| Pipeline potential (2–3 years) | ~$40m | — |
The contracted revenue provides near-term visibility, whilst the broader pipeline offers potential upside if Hydrix can convert additional engagements into signed contracts. The company’s ability to secure predominantly new international clients suggests its engineering capability is resonating beyond its existing customer base.
Cash position and director support
Cash on hand stood at $0.6 million at 31 December 2025, up from $0.3 million in the prior corresponding period. The company is supported by a $2.2 million Letter of Comfort from Directors, providing financial backing as contracted revenue converts to cash receipts.
Operating expenses have been tightly managed whilst maintaining what the company describes as essential engineering capacity to support accelerated revenue growth. The modest cash position reflects the capital-light nature of Hydrix’s services business, where contracted project work generates progressive milestone payments.
The next major ASX story will hit our subscribers first
Executive Chairman outlines growth trajectory for calendar year 2026
Executive Chairman Gavin Coote emphasised the company’s commercial momentum heading into the second half of the financial year, with contracted sales providing increased revenue visibility.
Gavin Coote, Executive Chairman
“With these new client sales now contracted early in this calendar year, and alongside expected follow-on contracts from existing clients, the Company enters the June half with increasing revenue visibility and a positive growth outlook for CY2026.”
Coote noted the contract wins followed extensive international business development efforts over the past 12 to 18 months, targeting what he described as profitable business growth opportunities for the company. The wins highlight the capability of Hydrix’s multi-discipline engineering team to develop safety-critical, lifesaving medical devices.
Beyond the services business, Hydrix Medical continues to progress commercial discussions for its remote cardiac patient monitoring cloud platform, with the potential to establish recurring revenue streams. Whilst no contracts have been announced, recurring revenue would provide greater earnings stability compared to the current project-based model.
Key developments to watch:
- Hydrix Medical progressing commercial discussions for remote cardiac patient monitoring cloud platform
- Potential to establish recurring revenue streams alongside project-based services income
What to watch for in coming quarters
Several catalysts could influence Hydrix’s trajectory over the coming quarters as contracted revenue converts and the pipeline matures.
- Revenue recognition from the SynCardia contract and other new client projects throughout CY2026, which should support sequential revenue growth
- Conversion of follow-on contracts from existing client engagements, particularly from the 15 active relationships
- Progress on Hydrix Medical cardiac monitoring platform commercial discussions, which could establish recurring revenue streams
- Broader pipeline conversion towards the approximately $40 million potential over the next 2 to 3 years
The contracted $3.7 million provides near-term visibility, representing revenue that should flow through during calendar year 2026. Follow-on work from the SynCardia contract would depend on successful completion of the first development stage and SynCardia’s decision to proceed to subsequent phases.
The company’s services model means revenue is typically recognised as development milestones are achieved, providing relatively predictable timing once contracts are signed. Longer-term upside depends on Hydrix’s ability to convert the 15 active client engagements into contracted work at rates consistent with recent wins.
Stay Ahead on Medical Technology Breakthroughs
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with expert analysis. StockWire X delivers real-time alerts the moment market-moving announcements hit—click the “Free Alerts” button to get medical technology news in your inbox before the market responds.